Educational Symposium
New Era of Anemia of CKD After the Nobel Prize
October 23, 2020 | 01:00 PM - 02:00 PM
Location: Simulive
Session Description
Researchers who discovered how cells sense and adapt to changing oxygen availability were awarded the Nobel Prize in Physiology or Medicine in 2019. Hypoxia-inducible factor (HIF) is a master regulator of adaptive responses to hypoxia and controls the expression of erythropoietin. HIF-prolyl hydroxylase inhibitors stabilize the HIF complex and stimulate endogenous erythropoietin production, even in patients with kidney failure, and may have a role in suppressing the progression of CKD as well as renal anemia.
This symposium covers the basic mechanisms of oxygen sensing and novel therapeutic approaches of anemia in CKD using the oxygen-sensing system.
Support is provided by an educational grant from AstraZeneca Pharmaceuticals LP in collaboration with FibroGen.
Learning Objective(s)
- Describe oxygen-sensing mechanisms
- Discuss appropriate use of HIF-prolyl hydroxylase inhibitors
Learning Pathway(s)
- Chronic Kidney Disease
Moderator
- Jodie L. Babitt, MD
Presentations
-
Introduction
01:00 PM - 01:10 PM
Jodie L. Babitt, MD
-
Oxygen Biology and the Nobel Prize
01:10 PM - 01:35 PM
Volker H. Haase, MD, DrMed
-
New Era of Anemia Treatment
01:35 PM - 02:00 PM
Masaomi Nangaku, MD, PhD
